Sphere Medical : Director's Dealing

Sphere Medical Holding plc



For Immediate Release                                                                                30 June 2014

Sphere Medical Holding plc

Director's Dealing

Cambridge, UK, 30 June 2014: Sphere Medical Holding plc (AIM: SPHR.L) ("Sphere Medical" or "the Company"), a leading developer of innovative monitoring and diagnostic products for the critical care setting, was informed on 27 June 2014 that earlier that day Dr. Wolfgang Rencken, Chief Executive Officer, purchased 11,970 ordinary shares in Sphere Medical at a price of 25p per share. Following this purchase Dr. Rencken has a beneficial interest in 11,970 ordinary shares representing 0.02% of the Company's issued ordinary share capital.

For further information, please contact:

Sphere Medical Holding plc	Tel: [phone]
Dr. Wolfgang Rencken, Chief Executive Officer
Matthew Hall, Chief Financial Officer
Peel Hunt LLP	Tel: [phone]
James Steel
Clare Terlouw
Jock Maxwell Macdonald
finnCap	Tel: [phone]
Geoff Nash / Simon Hicks
Stephen Norcross
Consilium Strategic Communications	Tel: [phone] [e-mail]
Mary-Jane Elliott
Amber Bielecka
Matthew Neal
Ivar Milligan

Notes for Editors

Sphere Medical (AIM: SPHR.L), is a medical device company developing a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.

Sphere Medical's products deliver real time analysis of blood gases, electrolytes and drug levels with laboratory accuracy, at the patient's bedside.  Sphere Medical's products can be used in a wide range of medical applications, enabling faster clinical decision making and improved patient outcomes, whilst reducing costs for healthcare payers.

Sphere Medical entered into a collaboration agreement with Ortho-Clinical Diagnostics, Inc. for the development of Proxima and enhancement of Sphere's operational and production capabilities in 2013. Proxima received CE marking under the EU Medical Devices Directive in June 2014. 

Sphere Medical has a number of partnerships with industry leading medical device companies and has received a strategic investment from Johnson & Johnson Development Corporation.  Other significant investors include Life Sciences Partners (LSP Life Sciences Fund).

This information is provided by RNS

The company news service from the London Stock Exchange

ENDRDSGMGZVKNKGDZM